EPICS Conference Coverage ESMO 2020 Breast Cancer Highlights

Practice changes and horizon openings from ESMO 2020 and beyond: triple-negative breast cancer, HR+/HER2+ early and metastatic breast cancer.

October 5 & 14, 2020


Joyce A. O’Shaughnessy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US

Nadia Harbeck


Nadia Harbeck, MD, PhD

Ludwig-Maximilians-University of Munich – Breast Center, Germany

Faculty Members

Adam Brufsky, MD, PhD
UPMC Hillman Cancer Center, Pittsburgh, PA, US

David Cameron, MD
Edinburgh University, Scotland

Pierfranco Conte, MD
University of Padua, Italy

Joseph Gligorov, MD, PhD
Tenon Hospital, Paris, France

Antonio Llombart-Cussac, MD, PhD
Hospital Arnau de Vilanova, Universidad Catolica Valencia, Spain

Andreas Schneeweiss, MD
Heidelberg University Hospital, Germany

Sample Report

Start discovering the insights

View Report


Aptitude Health conducted a series of online breast cancer expert forums focused on current and emerging approaches in triple-negative breast cancer, and on advances in HR+/HER2+ early stage and metastatic breast cancer. Life science partners had the ability to silently observe these important and timely online faculty discussions and received a comprehensive summary report including customized content specific to their products and areas of expertise.


Day 1 | EPICS Advisory Board Session TNBC and HR+ BC

The faculty, consisting of top breast cancer experts, will share their views via a 3-hour interactive virtual discussion on the newest clinical data, current treatment approaches, and their vision for how the landscape is likely to change in the future. Each clinical data presentation will be followed by a moderated discussion. During this first EPICS session, all stages of triple-negative breast cancer will be discussed.

Day 2 | EPICS Advisory Board Session HR+/HER2+
The clinical expert faculty will share their views during a 3-hour virtual discussion on the newest clinical data and treatment evolutions specific to HR+/HER2+ breast cancer.

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.